Metabolic syndrome and illness severity predict relapse at 1-year follow-up in schizophrenia: The FACE-SZ cohort
J. Clin. Psychiatry. 2018-09-18; 79(6):
DOI: 10.4088/JCP.17m12007
Read on PubMed
1. J Clin Psychiatry. 2018 Sep 18;79(6):17m12007. doi: 10.4088/JCP.17m12007.
Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in
Schizophrenia: The FACE-SZ Cohort.
Godin O(1)(2)(3), Leboyer M(2)(4), Schürhoff F(2)(4), Llorca PM(2)(5), Boyer
L(2)(6), Andre M(2)(7), Andrianarisoa M(2)(4), Aouizerate B(2)(8)(9), Berna
F(2)(10), Capdevielle D(2)(7), Chereau I(2)(5), Dorey JM(2)(11), Dubertret
C(2)(12), Dubreucq J(2)(13), Faget C(2)(14), Lancon C(2)(14), Leignier S(2)(13),
Mallet J(2)(12), Misdrahi D(2)(8)(15), Passerieux C(2)(16), Rey R(2)(11), Roux
P(2)(16), Vidailhet P(2)(10), Costagliola D(3), Fond G(2)(6); FACE-SZ
(FondaMental Academic Centers of Expertise for Schizophrenia) Group.
Author information:
(1)Institut Pierre Louis d’Epidémiologie et de Santé Publique, UMR_S 1136,
Hôpital La Salpêtriere, 75651 Paris Cédex 13, France. .
(2)FondaMental Fondation, Créteil, France.
(3)Sorbonne University, UPMC University Paris 06, UMR_S 1136, Institut Pierre
Louis d’Epidémiologie et de Santé Publique and INSERM, UMR_S 1136, Institut
Pierre Louis d’Epidémiologie et de Santé Publique, F-75013, Paris, France.
(4)INSERM, U955, Equipe 15 Genetic Psychiatry, Creteil; University Paris-Est,
UMR-S955, UPEC, Creteil, France.
(5)CMP B, CHU, EA 7280 Faculté de Médecine, Auvergne University,
Clermont-Ferrand France.
(6)Psychiatric Department University, CHU Sainte-Marguerite, Marseille, France.
(7)Psychiatric Emergency Department, CHRU Montpellier and INSERM U1061,
Montpellier University, Montpellier.
(8)Charles Perrens Hospital, Bordeaux University, Bordeaux, France.
(9)INSERM, Physiopathology of Neuronal Plasticity Unit, U862, Bordeaux, France.
(10)Strasbourg Hospital, Strasbourg University, INSERM U1114, Strasbourg,
France.
(11)INSERM U1028, CNRS UMR5292, Claude Bernard Lyon 1 University, Team PSYR2, Le
Vinatier Hospital, Bron, France.
(12)AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, INSERM
U894, Paris Diderot University, Sorbonne, Paris, France.
(13)Psychosocial Rehabilitation Expert Center, CH Alpes Isère, Grenoble, France.
(14)Marseille Hospital (AP-HM), University Department of Psychiatry, Marseille,
France.
(15)CNRS UMR 5287-INCIA, Bordeaux, France.
(16)Versailles Hospital, Versailles Saint-Quentin-en-Yvelines University,
Versailles, France.
OBJECTIVE: Predicting relapse is a major challenge in schizophrenia from a
clinical and medico-economic point of view. During recent decades, major
psychiatric disorders have been found to be extensively associated with
metabolic disorders, even before the illness onset, with a prevalence estimated
to be 35% in this population. However, no study to date has, to our knowledge,
explored the potential impact of metabolic syndrome (MetS) on relapse.
METHODS: From 2010 to 2016, 185 patients (mean age = 32 years) with a DSM-IV-TR
diagnosis of schizophrenia were included in the FondaMental Academic Centers of
Expertise for Schizophrenia (FACE-SZ) cohort and followed up for 1 year.
Multivariable logistic regression was performed to estimate the adjusted odds
ratio for relapse.
RESULTS: Thirty-seven percent of stabilized outpatients with schizophrenia (mean
illness duration = 11 years) experienced a relapse at least once during the 1
year of follow-up. MetS strongly predicted relapse at 1 year, independently of
illness severity, insight into illness, and treatment characteristics (including
medication compliance). Patients with MetS at baseline had a 3 times higher risk
(95% CI, 1.1-8.4) of experiencing a new episode of psychosis during the 12
months of follow-up.
CONCLUSIONS: Further studies should determine if reducing or preventing MetS
could help to protect subjects with schizophrenia from relapse.
© Copyright 2018 Physicians Postgraduate Press, Inc.
DOI: 10.4088/JCP.17m12007
PMID: 30257079 [Indexed for MEDLINE]